BioDlink Clarifies Outstanding Share Options Amid Takeover Process

TOT BIOPHARM International Co. Ltd. ( (HK:1875) ) just unveiled an update.

BioDlink International Company Limited has issued a clarification related to its earlier disclosure under Rule 3.8 of the Hong Kong Takeovers Code, in the context of ongoing takeover offers involving Wuxi Biologics. The board clarified that, following the vesting of 142,000 share options on 1 March 2026, the company now has 7,632,600 outstanding share options, comprising 7,490,600 vested unexercised options and 142,000 unvested options, with all other information in the prior announcement remaining unchanged.

The clarification refines the capital structure data available to investors and regulators during the live offer period, helping market participants accurately assess the company’s fully diluted share base and potential equity overhang. Directors have accepted collective responsibility for the accuracy of the revised figures, underscoring the importance of precise option accounting in takeover-related disclosures and providing stakeholders with greater transparency as the transaction process continues.

The most recent analyst rating on (HK:1875) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on TOT BIOPHARM International Co. Ltd. stock, see the HK:1875 Stock Forecast page.

More about TOT BIOPHARM International Co. Ltd.

BioDlink International Company Limited, listed in Hong Kong under stock code 1875, operates in the biopharmaceutical sector. The company is currently the subject of takeover offers involving Wuxi Biologics and has issued several joint documents and announcements in connection with these offers, reflecting an active phase of corporate transaction and regulatory disclosure under the Hong Kong Takeovers Code.

Average Trading Volume: 3,619,731

Technical Sentiment Signal: Buy

Current Market Cap: HK$3.13B

See more insights into 1875 stock on TipRanks’ Stock Analysis page.